Okyo Pharma Ltd (OKYO) Ord NPV
OKYO Pharma Limited is a United Kingdome-based biopharmaceutical company. The Company’s operating segment is research and development of biotechnological and pharmaceutical products. The Company focuses on G-protein coupled receptors (GPCR) based therapeutics for eye diseases and non-opioid analgesics for chronic pain. It is developing drug candidates for the treatment of dry-eye, uveitis, ocular and chronic pain. The Company’s therapeutic approach is to develop drug candidates that target inflammatory pathways using membrane-tethered ligand technology. The Company focuses to suppress the inflammation associated with the uveitis using its anti-inflammatory compound. Its product candidates include OKYO-0101 and OHYO-0201. The OKYO-0101 is focused on uveitis and allergic conjunctivitis. The OHYO-0201 is focused on ocular pain and chronic pain. OKYO Pharma US Inc is the subsidiary of the Company.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.